| Serial Number | 87729173 |
| Word Mark | NUGLEA |
| Filing Date | Wednesday, December 20, 2017 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, January 31, 2022 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, October 30, 2018 |
| Goods and Services | Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post-intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, January 8, 2018 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | BIOHAVEN PHARMACEUTICAL IRELAND DAC |
| Party Type | 21 - New Owner After Publication |
| Legal Entity Type | 99 - Other |
| Address | DUBLIN 4 D04TR29 IE |
| Party Name | Biohaven Pharmaceutical Holding CompanyLimited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | New Haven, CT 06510 |
| Party Name | Biohaven Pharmaceutical Holding CompanyLimited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | New Haven, CT 06510 |
| Event Date | Event Description |
| Monday, January 31, 2022 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, January 31, 2022 | ABANDONMENT - NO USE STATEMENT FILED |
| Wednesday, June 23, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, June 22, 2021 | SOU EXTENSION 5 GRANTED |
| Monday, June 21, 2021 | SOU EXTENSION 5 FILED |
| Monday, June 21, 2021 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, December 23, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, December 21, 2020 | SOU EXTENSION 4 GRANTED |
| Monday, December 21, 2020 | SOU EXTENSION 4 FILED |
| Monday, December 21, 2020 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, August 19, 2020 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Wednesday, July 1, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, June 30, 2020 | SOU EXTENSION 3 GRANTED |
| Wednesday, June 17, 2020 | SOU EXTENSION 3 FILED |
| Tuesday, June 30, 2020 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Wednesday, June 17, 2020 | SOU TEAS EXTENSION RECEIVED |
| Monday, February 3, 2020 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Monday, February 3, 2020 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Monday, January 13, 2020 | WITHDRAWAL OF ATTORNEY GRANTED |
| Monday, January 13, 2020 | TEAS WITHDRAWAL OF ATTORNEY RECEIVED |
| Saturday, December 21, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, December 19, 2019 | SOU EXTENSION 2 GRANTED |
| Thursday, December 19, 2019 | SOU EXTENSION 2 FILED |
| Thursday, December 19, 2019 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, October 23, 2019 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Wednesday, October 23, 2019 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Wednesday, June 5, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, June 3, 2019 | SOU EXTENSION 1 GRANTED |
| Monday, June 3, 2019 | SOU EXTENSION 1 FILED |
| Monday, June 3, 2019 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, December 25, 2018 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, October 30, 2018 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, October 30, 2018 | PUBLISHED FOR OPPOSITION |
| Wednesday, October 10, 2018 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Friday, September 21, 2018 | ASSIGNED TO LIE |
| Thursday, September 6, 2018 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, August 31, 2018 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, August 30, 2018 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, August 30, 2018 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, March 29, 2018 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, March 29, 2018 | NON-FINAL ACTION E-MAILED |
| Thursday, March 29, 2018 | NON-FINAL ACTION WRITTEN |
| Tuesday, March 27, 2018 | ASSIGNED TO EXAMINER |
| Monday, January 8, 2018 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Saturday, December 23, 2017 | NEW APPLICATION ENTERED |